Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the greek population

Molecular Diagnosis and Therapy

Volumn 16, Issue 1, 2012, Pages 29-34

  Vasilopoulos, Yiannis ^a   Manolika, Marilena ^a   Zafiriou, Efterpi ^b   Sarafidou, Theologia ^a   Bagiatis, Vasilis ^a   Krüger Krasagaki, Sabine ^c   Tosca, Androniki ^c   Patsatsi, Aikaterini ^d   Sotiriadis, Dimitris ^d   Mamuris, Zissis ^a   Roussaki Schulze, Angeliki ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GENOMIC DNA; INFLIXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENETIC POLYMORPHISM; GREECE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS SEVERITY INDEX; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREECE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTORS;

EID: 84857578226     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11594660     Document Type: Article

References (18)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71 (Pubitemid 47069537)
2. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699-711 (Pubitemid 43090738)
3. O'Rielly DD, Rahman P. Pharmacogenetics of psoriasis. Pharmacogenomics 2011; 12 (1): 87-101
4. Ryan C, Menter A, Warren RB. The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. Mol Diagn Ther 2010; 14 (2): 81-93
5. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73
6. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their costeffectiveness. Health Technol Assess 2006; 10: 1-248
7. Plenge RM, Criswell LA. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr Opin Rheumatol 2008; 20: 145-52 (Pubitemid 351339885)
8. Vasilopoulos Y, Bagiatis V, Stamatopoulou D, et al. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNFα response in rheumatoid arthritis. Clin Exp Rheumatol 2011; 29 (4): 701-4
9. Warren RB, Smith RL, Campalani E, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009; 160 (2): 438-41
10. Lin DY, Hu Y, Huang BE. Simple and efficient analysis of disease association with missing genotype data. Am J Hum Genet 2008; 82: 444-52 (Pubitemid 351726097)
11. Kooloos WM, de Jong DJ, Huizinga TW, et al. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today 2007; 12: 125-31 (Pubitemid 46176662)
12. Haider AS, Cardinale IR, Whynot JA, et al. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc 2007; 12 (1): 9-15 (Pubitemid 46763029)
13. van Heel DA, Udalova IA, De Silva AP, et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. Hum Mol Genet 2002; 11 (11): 1281-9 (Pubitemid 34555525)
14. Glossop JR, Dawes PT, Nixon NB, et al. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R1227-34
15. Rego-Pérez I, Fernández-Moreno M, Blanco FJ. Gene polymorphisms and pharmacogenetics in rheumatoid arthritis. Curr Genomics 2008; 9: 381-93
16. Kang CP, Lee KW, Yoo DH, et al. The influence of a polymorphismat position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 547-52 (Pubitemid 41511149)
17. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157 (1): 68-73 (Pubitemid 46934281)
18. Woolf RT, Smith CH. How genetic variation affects patient response and outcome to therapy for psoriasis. Expert Rev Clin Immunol 2010; 6 (6): 957-66